ReAlta Life Sciences Gains EMA Orphan Drug Designation for Pegtarazimod in Graft-Versus-Host Disease Treatment

The European Medicines Agency (EMA) has granted Orphan Drug Designation to RLS-0071 (pegtarazimod) for the treatment of Graft-versus-Host Disease (GvHD), providing significant regulatory benefits for ReAlta Life Sciences' clinical development program. This designation, supported by preliminary data from the ongoing Phase 2 trial, recognizes the potential of pegtarazimod to address a rare and life-threatening condition that affects fewer than five in 10,000 people in the European Union.

The EMA Orphan Drug Designation follows the U.S. Food and Drug Administration's (FDA) previous granting of both Orphan Drug Designation and Fast Track Designation for pegtarazimod in the treatment of acute GvHD (aGvHD) in August 2024. These regulatory milestones validate the company's novel dual-targeting approach that modulates both neutrophil and complement-mediated inflammation, offering a potentially more targeted intervention compared to broadly immunosuppressive treatments.

ReAlta is currently enrolling patients in its Phase 2, open-label clinical trial (NCT06343792) evaluating pegtarazimod for hospitalized patients with steroid-refractory aGvHD at clinical sites in the United States, Germany, and Spain. The trial includes patients with moderate to very severe disease, particularly focusing on lower gastrointestinal aGvHD, which is the most difficult to treat and carries the highest mortality rates.

Pegtarazimod represents a innovative therapeutic approach as a 15-amino-acid peptide that uniquely targets both humoral and cellular inflammation. The medication works by selectively inhibiting complement activation at C1, as well as myeloperoxidase (MPO) activity and neutrophil extracellular trap (NET) formation—key mechanisms that drive the inflammatory cascade and tissue damage when donor immune cells attack recipient tissues following hematopoietic stem cell transplantation.

The EMA Orphan Drug Designation provides pharmaceutical companies with substantial benefits including reduced regulatory fees, clinical protocol assistance, and up to 10 years of market exclusivity in the European Union if the drug receives approval. This regulatory support accelerates the development timeline and enhances the commercial viability of treatments for rare diseases that otherwise might not attract sufficient investment due to small patient populations.

For patients suffering from steroid-refractory aGvHD, this development represents hope for a more targeted therapeutic option that addresses the specific pathways driving tissue damage while preserving beneficial immune function. The company expects to report data from additional cohorts of patients enrolled in the Phase 2 trial in 2026, potentially bringing this innovative treatment closer to European patients who currently have limited options for this devastating condition.